Analysed TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) News Sources
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
30-09-2026
yahoo.com
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
30-09-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
30-09-2026
yahoo.com
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
30-09-2026
yahoo.com
Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative
01-10-2026
yahoo.com
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
01-10-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading
07-10-2026
yahoo.com
What is the current price of TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS)?
The current price of TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) is $33.85.
TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) since the previous trading day is $-1.9.
TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) since the previous trading day is -5.3147%.
What is the most recent average sentiment score for TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS)?
The most recent average sentiment score for TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) is 67 out of 100.
What is the most recent average sentiment for TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS)?
The most recent sentiment for TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS) is .
SEC-8K** Filing Available For TAKEDA PHARMACEUTICAL CO LTD (TKPHF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.